# Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

> **NCT05954442** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 203 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- Metastatic Breast Cancer
- Mutation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Investigator's Choice of Chemotherapy

## Key facts

- **NCT ID:** NCT05954442
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-13
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 203 (ESTIMATED)
- **Last updated:** 2024-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05954442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05954442, "Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05954442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*